Low-volume regional lymph node metastasis in endometrial cancer – 2024 update

Česká verze

Authors: Dita Münzová ¹ ; Petra Bretová ^1,2 ; Jitka Hausnerova ³ ; Markéta Bednaříková ⁴ ; Luboš Minář ¹ ; Vít Weinberger ¹
Authors place of work: Gynekologicko-porodnická klinika LF MU a FN Brno ¹; Porodnická a gynekologická klinika LF UK a FN Hradec Králové ²; Ústav patologie, LF MU a FN Brno ³; Interní hematologická a onkologická klinika LF MU a FN Brno ⁴
Published in the journal: Ceska Gynekol 2025; 90(2): 158-162
Category: Přehledová práce
doi: https://doi.org/10.48095/cccg2025158

Summary

Due to the implementation of sentinel lymph node ultrastaging, the prevalence of isolated tumor cells and micrometastases have increased. This literature review comprises of articles published between January 2019 and September 2024 aiming at low-volume metastases in regional lymph nodes, their prognosis, and links to molecular classification. Micrometastases are currently considered as having metastatic lymph node involvement; however, they have a better prognosis than macrometastases. Accordingly, therapy is tailored. In contrast, isolated tumor cell presence is not considered metastatic involvement according to International Federation of Gynecology and Obstetrics (FIGO) 2023 staging and does not affect the therapeutic procedure because their significant prognostic importance has not been proven so far.

Keywords:

endometrial cancer – sentinel lymph node – ultrastaging – low-volume metastasis – isolated tumor cells – micrometastases

Zdroje

1. Krejčí D, Mužík J, Šnábl I et al. Portál epidemiologie novotvarů v ČR. Masarykova univerzita, Brno. 2024 [online]. Dostupné z: https: //www.svod.cz.

2. Concin N, Matias-Guiu X, Vergote I et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 2021; 31 (1): 12–39. doi: 10.1136/ijgc-2020-002230.

3. Concin N, Planchamp F, Abu-Rustum NR et al. European Society of Gynaecological Oncology quality indicators for the surgical treatment of endometrial carcinoma. Int J Gynecol Cancer 2021; 31 (12): 1508–1529. doi: 10.1136/ijgc-2021-003178.

4. Burg LC, Hengeveld EM, In‘t Hout J et al. Ultrastaging methods of sentinel lymph nodes in endometrial cancer – a systematic review. Int J Gynecol Cancer 2021; 31 (5): 744–753. doi: 10.1136/ijgc-2020-001964.

5. Berek JS, Matias-Guiu X, Creutzberg C et al; Endometrial Cancer Staging Subcommittee, FIGO Women’s Cancer Committee. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023; 162 (2): 383–394. doi: 10.1002/ijgo. 14923.

6. Kosťun J, Pešta M, Sláma J et al. One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients. J Surg Oncol 2019; 119 (3): 361–369. doi: 10.1002/jso. 25322.

7. Cuadras M, Planas J, Celma A et al. Application of One-Step Nucleic Acid amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review. BMC Cancer 2022; 22 (1): 357. doi: 10.1186/s12885-022-09355-0.

8. Diestro MD, Berjón A, Zapardiel I et al. One--Step Nucleic Acid amplification (OSNA) of sentinel lymph node in Early-Stage Endometrial cancer: spanish multicenter study (ENDO-OSNA). Cancers (Basel) 2021; 13 (17): 4465. doi: 10.3390/cancers13174465.

9. Chacon E, Boria F, Lyer RR et al. SENECA study: staging endometrial cancer based on molecular classification. Int J Gynecol Cancer 2024; 34: 1313–1321. doi: 10.1136/ijgc-2024- 005711.

10. Kosťun J, Ismail KM, Pešta M et al. One--Step Nucleic Acid amplification analysis of sentinel nodes in endometrial cancer versus ultrastaging: first long-term follow-up data of discordant cases. Cancer Rep (Hoboken) 2024; 7 (12): e70082. doi: 10.1002/cnr2. 70082.

11. Hambálek J, Maděrka M, Kolečková M et al. Nízkoobjemové postižení uzlin u karcinomu endometria. Ceska gynekol 2019; 84 (6): 458–462.

12. Mueller JJ, Pedra Nobre S, Braxton K et al. Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma. Gynecol Oncol 2020; 157 (3): 619–623. doi: 10.1016/j.ygyno.2020. 03.025.

13. De Vitis LA, Fumagalli D, Schivardi G et al. Incidence of sentinel lymph node metastases in apparent early-stage endometrial cancer: a multicenter observational study. Int J Gynecol Cancer 2024; 34 (5): 689–696. doi: 10.1136/ijgc-2023-005173.

14. Buda A, Paniga C, Taskin S et al. The risk of recurrence in endometrial cancer patients with low-volume metastasis in the sentinel lymph nodes: a retrospective multi-institutional study. Cancers (Basel) 2023; 15 (7): 2052. doi: 10.3390/cancers15072052.

15. Lavecchia M, Jang JH, Lee HJ et al. Sentinel lymph node biopsy in endometrial cancer: the new norm – a multicentre, international experience. Surg Oncol 2023; 48: 101922. doi: 10.1016/j.suronc.2023.101922.

16. Matsuo K, Chen L, Neuman MK et al. Lymph node isolated tumor cells in patients with endometrial cancer. JAMA Netw Open 2024; 7 (3): e240988. doi: 10.1001/jamanetworkopen. 2024.0988.

17. García Pineda V, Hernández Gutiérrez A, Gracia Segovia M et al. Low-volume nodal metastasis in endometrial cancer: risk factors and prognostic significance. J Clin Med 2020; 9 (6): 1999. doi: 10.3390/jcm9061999.

18. Carretta A. Clinical value of nodal micrometastases in patients with non-small cell lung cancer: time for reconsideration? J Thorac Dis 2016; 8 (12): E1755–E1758. doi: 10.21037/jtd.2016.12.83.

19. Sloothaak DA, Sahami S, van der Zaag-Loonen HJ et al. The prognostic value of micrometastases and isolated tumour cells in histologically negative lymph nodes of patients with colorectal cancer: a systematic review and meta-analysis. Eur J Surg Oncol 2014; 40 (3): 263–269. doi: 10.1016/j.ejso.2013. 12.002.

20. Ignatov A, Lebius C, Ignatov T et al. Lymph node micrometastases and outcome of endometrial cancer. Gynecol Oncol 2019; 154 (3): 475–479. doi: 10.1016/j.ygyno.2019. 07.018.

21. Ghoniem K, Larish AM, Dinoi G et al. Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: an international multi-institutional study. Gynecol Oncol 2021; 162 (3): 590–598. doi: 10.1016/j.ygyno.2021.06.031.

22. Bogani G, Mariani A, Paolini B et al. Low-volume disease in endometrial cancer: the role of micrometastasis and isolated tumor cells. Gynecol Oncol 2019; 153 (3): 670–675. doi: 10.1016/j.ygyno.2019.02.027.

23. Backes FJ, Felix AS, Plante M et al. Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: to treat or not to treat? Gynecol Oncol 2021; 161 (2): 347–352. doi: 10.1016/j.ygyno.2021.02.017.

24. Cucinella G, Schivardi G, Zhou XC et al. Prognostic value of isolated tumor cells in sentinel lymph nodes in low risk endometrial cancer: results from an international multi-institutional study. Int J Gynecol Cancer 2024; 34 (2): 179–187. doi: 10.1136/ijgc-2023-005032.

25. Schivardi G, Cucinella G, Mariani A et al. 2022-RA-987-ESGO Molecular characterization of endometrial cancer with low volume metastasis in the sentinel lymph node: a multicentric international study. Int J Gynecol Cancer 2022; 32 (Suppl 2): A124.2. doi: 10.1136/ijgc-2022-ESGO.268.

26. Rios-Doria E, Abu-Rustum NR, Alektiar KM et al. Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer. Int J Gynecol Cancer 2024; 34 (9): 1373–1381. doi: 10.1136/ijgc-2024-005522.

27. Sullivan SA, Hawkins G, Zhao X et al. Genomic profiling of endometrial cancer and relationship with volume of endometrial cancer disease spread. Gynecol Oncol Rep 2021; 36: 100720. doi: 10.1016/j.gore.2021.100720.

28. Watanabe T, Nanamiya H, Kojima M et al. Clinical relevance of oncogenic driver mutations identified in endometrial carcinoma. Transl Oncol 2021; 14 (3): 101010. doi: 10.1016/j.tranon.2021.101010.

29. de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009; 361 (7): 653–663. doi: 10.1056/NEJMoa09 04832.

ORCID autorů

D. Münzová 0009-0004-1157-252X

P. Bretová 0000-0003-1082-433X

J. Hausnerová 0000-0002-0522-1916

M. Bednaříková 0000-0003-3189-7028

L. Minář 0000-0001-9088-5428

V. Weinberger 0000-0003-4858-1951

Doručeno/Submitted: 30. 1. 2025

Přijato/Accepted: 3. 2. 2025

MUDr. Petra Bretová, Ph.D.

Gynekologicko-porodnická klinika

LF MU a FN Brno